![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » CytoSorbents’ Antithrombotic Removal System Named FDA Breakthrough Device Again
CytoSorbents’ Antithrombotic Removal System Named FDA Breakthrough Device Again
![Breakthrough Status](https://www.fdanews.com/ext/resources/test/Device_Images6/Breakthrough-Status.gif?t=1620169812&width=430)
August 18, 2021
CytoSorbents has received a second Breakthrough Device designation from the FDA for its DrugSorb-ATR antithrombotic removal system.
The blood purification device is used to reduce the risk of life-threatening bleeding in patients who have been taking oral anticoagulants and who need urgent surgery.
The new designation is for removal of the anticoagulants apixaban and rivaroxaban in a cardiopulmonary bypass circuit to reduce the likelihood of serious bleeding during cardiothoracic surgery.
The company previously received a Breakthrough Device designation from the agency in April 2020 for use of the device to remove the blood thinner ticagrelor during cardiothoracic surgery.
Upcoming Events
-
21Oct